Medtronic settles states' probe into Infuse marketing for $12 mln
December 13, 2017 at 12:58 PM EST
BOSTON, Dec 13 (Reuters) - Medtronic Plc has agreed to pay $12 million to resolve claims that the company engaged in a deceptive marketing strategy to promote its Infuse bone graft product used in spinal surgery, the Massachusetts attorney general said on Wednesday.